Serum miRNA Biomarkers for Epilepsy Drug Response Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable biomarkers to predict an individual patient's response to anti-epileptic drugs, and existing diagnostic tools like EEG are complex and not suitable for continuous monitoring, especially in pediatric patients.
Innovation Solution
The use of microRNAs hsa-miR-106b-5p and hsa-miR-15a-5p as biomarkers, quantified by reverse transcription-qPCR, to assess seizure frequency and drug response in patients with epilepsy, providing a non-invasive and accessible method independent of blood sample hemolysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If EEG is used to monitor seizure frequency, then measurement precision is improved, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent replaces the complex mechanical/electrical EEG monitoring system with a biochemical detection system based on miRNA quantification in serum samples. Instead of using electrodes and complex signal processing to detect seizures, the invention uses reverse transcription-qPCR to measure miRNA levels, which serve as biomarkers for seizure frequency. This substitution dramatically simplifies the monitoring process while maintaining measurement capability.
Solution Approach 2:
The patent introduces miRNAs as intermediary biomarkers that indirectly reflect seizure frequency. Rather than directly monitoring electrical brain activity through EEG, the system uses miRNA levels in serum as a mediator that correlates with seizure occurrence. This intermediary approach simplifies the measurement system while providing continuous monitoring capability through routine blood tests.
2Measurement precision
If EEG is used for seizure monitoring, then measurement precision is improved, but ease of operation deteriorates for pediatric patients
Solution Approach 1:
The patent replaces the cumbersome EEG procedure with a simple serum sample collection and miRNA quantification process. For pediatric patients, this means replacing complex electrode placement and prolonged monitoring with a routine blood test that can be performed quickly and comfortably, significantly improving ease of operation and patient compliance.
Solution Approach 2:
The patent uses serum samples as a copy or surrogate for direct brain activity measurement. Instead of requiring patients to undergo complex EEG procedures, the system analyzes miRNA copies present in serum that reflect brain seizure activity. This copying approach makes monitoring as easy as a routine blood test while preserving the ability to detect seizure frequency.
3Measurement precision
If multiple metabolites are measured to determine drug-resistant epilepsy, then measurement precision is improved, but device complexity and loss of time increase
Solution Approach 1:
The patent extracts the essential diagnostic information from a complex metabolic profile by focusing on specific miRNA biomarkers. Instead of measuring multiple metabolites as in prior art, the invention isolates and quantifies particular miRNAs (such as miR-106b-5p and miR-15a-5p) that are specifically associated with drug-resistant epilepsy. This extraction approach maintains diagnostic precision while dramatically reducing test complexity and time requirements.
Solution Approach 2:
The patent extracts only the most relevant miRNA biomarkers from the complex regulatory network in epilepsy. By focusing on specific miRNAs that have been shown to correlate with drug resistance, the system eliminates the need to measure multiple metabolites, thereby reducing device complexity and analysis time while preserving the ability to accurately diagnose drug-resistant epilepsy.
4Ease of operation
If miRNA levels are used as biomarkers, then ease of operation and accessibility are improved, but measurement precision may deteriorate due to hemolysis
Solution Approach 1:
The patent converts the potential harm of hemolysis into a beneficial diagnostic feature. Instead of treating hemolysis as a confounding factor that reduces measurement precision, the invention uses the presence of hemolysis markers (such as miR-451a from red blood cells) as additional diagnostic information. By measuring both hemolysis indicators and target miRNAs, the system can distinguish between miRNA changes due to hemolysis and those due to seizure activity, thereby maintaining measurement precision while preserving the ease of operation of simple serum collection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These miRNAs allow discrimination between different seizure frequencies and response to therapies, indicating drug resistance, with stable serum levels enabling routine clinical application.
Implementation Method 1
quantified by reverse transcription-qPCR
Implementation Method 2
reverse transcription-qPCR
Data Source
AI summary
The invention concerns an in vitro method for assessing the epileptic condition of a patient. The method comprises determining in a serum sample from said patient the level of a mi-croRNA selected from hsa-miR-106b-5p and hsa-miR-15a-5p, said level being indicative of the epileptic seizure frequency in the patient.